ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET
ANI Pharmaceuticals (NASDAQ: ANIP) has scheduled its first quarter 2025 financial results announcement for Friday, May 9, 2025, before market opening. The company will host a conference call at 8:00 a.m. ET to discuss the results.
Key executives participating in the call include President and CEO Nikhil Lalwani, SVP Finance and CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz. Investors can access the call via toll-free number 800-225-9448 using Conference ID 4921902.
The webcast will be available live and for replay on the company's website under the Investors section. A replay option will be accessible for two weeks by calling 800-753-8591 with access code 4921902.
ANI Pharmaceuticals (NASDAQ: ANIP) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per venerdì 9 maggio 2025, prima dell'apertura del mercato. L'azienda ospiterà una conferenza telefonica alle 8:00 a.m. ET per discutere i risultati.
I principali dirigenti che parteciperanno alla chiamata includono il Presidente e CEO Nikhil Lalwani, il SVP Finanza e CFO Stephen P. Carey, e il Responsabile delle Malattie Rare Chris Mutz. Gli investitori possono accedere alla chiamata tramite il numero verde 800-225-9448 utilizzando l'ID Conferenza 4921902.
La trasmissione in diretta sarà disponibile e potrà essere riascoltata sul sito web dell'azienda nella sezione Investitori. Un'opzione di riascolto sarà accessibile per due settimane chiamando il numero 800-753-8591 con il codice di accesso 4921902.
ANI Pharmaceuticals (NASDAQ: ANIP) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para viernes 9 de mayo de 2025, antes de la apertura del mercado. La empresa llevará a cabo una conferencia telefónica a las 8:00 a.m. ET para discutir los resultados.
Los ejecutivos clave que participarán en la llamada incluyen al Presidente y CEO Nikhil Lalwani, al SVP de Finanzas y CFO Stephen P. Carey, y al Jefe de Enfermedades Raras Chris Mutz. Los inversores pueden acceder a la llamada a través del número gratuito 800-225-9448 usando el ID de Conferencia 4921902.
La transmisión en vivo estará disponible y se podrá reproducir nuevamente en el sitio web de la empresa en la sección de Inversores. Una opción de repetición estará accesible durante dos semanas llamando al 800-753-8591 con el código de acceso 4921902.
ANI Pharmaceuticals (NASDAQ: ANIP)는 2025년 5월 9일 금요일에 2025년 1분기 재무 결과 발표를 시장 개장 전에 예정하고 있습니다. 회사는 오전 8:00 ET에 결과를 논의하기 위해 컨퍼런스 콜을 개최합니다.
콜에 참여하는 주요 임원으로는 사장 겸 CEO Nikhil Lalwani, 재무 부사장 겸 CFO Stephen P. Carey, 희귀 질환 책임자 Chris Mutz가 있습니다. 투자자들은 무료 전화번호 800-225-9448을 통해 회의 ID 4921902를 사용하여 콜에 접속할 수 있습니다.
웹캐스트는 회사 웹사이트의 투자자 섹션에서 실시간으로 제공되며 재생할 수 있습니다. 재생 옵션은 800-753-8591로 전화하여 접근 코드 4921902를 입력하면 2주 동안 이용할 수 있습니다.
ANI Pharmaceuticals (NASDAQ: ANIP) a programmé l'annonce de ses résultats financiers pour le premier trimestre 2025 pour vendredi 9 mai 2025, avant l'ouverture du marché. L'entreprise tiendra une conférence téléphonique à 8h00 ET pour discuter des résultats.
Les principaux dirigeants participant à l'appel incluent le Président et CEO Nikhil Lalwani, le SVP Finance et CFO Stephen P. Carey, et le Responsable des Maladies Rares Chris Mutz. Les investisseurs peuvent accéder à l'appel via le numéro gratuit 800-225-9448 en utilisant l'ID de conférence 4921902.
Le webinaire sera disponible en direct et en replay sur le site web de l'entreprise dans la section Investisseurs. Une option de replay sera accessible pendant deux semaines en appelant le 800-753-8591 avec le code d'accès 4921902.
ANI Pharmaceuticals (NASDAQ: ANIP) hat die Bekanntgabe der finanziellen Ergebnisse für das erste Quartal 2025 auf Freitag, den 9. Mai 2025, vor Markteröffnung angesetzt. Das Unternehmen wird um 8:00 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen.
Zu den wichtigsten Führungskräften, die an dem Anruf teilnehmen, gehören Präsident und CEO Nikhil Lalwani, SVP Finanzen und CFO Stephen P. Carey sowie Leiter der seltenen Krankheiten Chris Mutz. Investoren können über die gebührenfreie Nummer 800-225-9448 mit der Konferenz-ID 4921902 auf den Anruf zugreifen.
Der Webcast wird live verfügbar sein und kann auf der Website des Unternehmens im Bereich Investoren wiederholt werden. Eine Wiederholungsoption ist für zwei Wochen unter der Nummer 800-753-8591 mit dem Zugangscode 4921902 verfügbar.
- None.
- None.
PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows:
| Date | Friday, May 9, 2025 | |
| Time | 8:00 a.m. ET | |
| Toll free (U.S.) | 800-225-9448 | |
| Conference ID | 4921902 | |
| Webcast (live and replay) | www.anipharmaceuticals.com, under the “Investors” section |
A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-753-8591 and entering access code 4921902.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.
Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com
SOURCE: ANI Pharmaceuticals, Inc.
FAQ
When will ANI Pharmaceuticals (ANIP) release Q1 2025 earnings?
How can investors access ANIP's Q1 2025 earnings call?
Who will be presenting at ANI Pharmaceuticals' Q1 2025 earnings call?
How long will ANIP's Q1 2025 earnings call replay be available?
